A phase I COVID-19 vaccine trial among SARS-CoV-2 seronegative and seropositive individuals in Uganda utilizing a self-amplifying RNA vaccine platform: Screening and enrollment experiencesCoronavirus Published on 2023-08-082024-09-05 Journal: Human vaccines & immunotherapeutics [Category] update2024, [키워드] COVID-19 enrolment SARS-CoV-2 Screening self-amplifying RNA Vaccine [DOI] 10.1080/21645515.2023.2240690 PMC 바로가기 [Article Type] Coronavirus
Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control studyArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 치료기술, 치료제, [키워드] 95% CI adjusted hazard ratio Antiviral ARMS clinical clinical condition Clinical improvement complications control arm COVID-19 COVID-19 patient Day defined early treatment Effect Efficacy enrolled enrolment faster Favipiravir female FPV investigated likelihood median median time mild case mild pneumonia multicentre Patient PCR-confirmed Pneumonia primary endpoint randomized control study RdRP RdRp inhibitor registry risk of COVID-19 SARS-CoV-2-infected patient score significantly higher supportive care sustained symptomatic Thailand Treatment viral clearance Viral detection [DOI] 10.1080/22221751.2022.2117092 PMC 바로가기
Comparison of maternal and neonatal outcomes of COVID-19 before and after SARS-CoV-2 omicron emergence in maternity facilities in Malawi (MATSurvey): data from a national maternal surveillance platformArticle Published on 2022-11-012022-11-16 Journal: The Lancet. Global health [Category] SARS, 변종, [키워드] Abstract adjusted age breath Clinical features COVID-19 death demographic demographic characteristics died enrolment event Fisher foundation health-care less Logistic regression material Maternal Melinda Gate National Neonatal Neonate Odds ratio outcome pandemic Patient platform Pregnancy pregnant pregnant patients reported SARS-CoV-2 SARS-COV-2 infection second wave Stillbirth sub-Saharan Africa Surveillance Symptom symptomatic symptoms of COVID-19 the SARS-CoV-2 translation Wellcome Trust [DOI] 10.1016/S2214-109X(22)00359-X PMC 바로가기
Interplay between demographic, clinical and polygenic risk factors for severe COVID-19Article Published on 2022-10-132022-11-15 Journal: International Journal of Epidemiology [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] 95% CI adjusted odds ratio Admission age antiviral response association co-morbidity conducted COVID-19 COVID-19 diagnosis Critical care death develop diagnosed with COVID-19 enrolment Epidemiology European Factor Factors General population genetic data genetic risk factor Genetic variant greater highest hospital Hospitalization identify IMPROVE individual interquartile range lowest median men morbidity obesity outcomes participant Pathway analysis Pathways Patient polygenic risk score polymorphism PRS reported risk risk factor risk prediction severe COVID-19 single-nucleotide Smokers socio-demographic UK biobank was performed [DOI] 10.1093/ije/dyac137 PMC 바로가기
Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trialArticle Published on 2022-09-022022-10-06 Journal: The Lancet. Respiratory Medicine [Category] 진단, [키워드] 1:1 Activation adjusted odds ratio age Analysis assigned block brensocatib clinical status common adverse event criteria death disorder dose double-blind enrolment enzyme hospital Hospital admission hospitalised IMPROVE in both group Infection infections inhibitor intention-to-treat population investigated investigator involved ISRCTN medication multicentre neutrophil Older outcome parallel-group participant pathogenesis of COVID-19 Patient patients Placebo placebo-controlled trial Primary outcome random random assignment randomised Randomly receive Registered reported required responsible risk factor safety population serine protease serine proteases severe disease stratified study drug supported the placebo group therapy Treatment Trial university web-based randomisation system were excluded WHO ordinal scale with COVID-19 [DOI] 10.1016/S2213-2600(22)00261-2 PMC 바로가기 [Article Type] Article
Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trialRandomized Controlled Trial Published on 2022-08-262022-10-05 Journal: Trials [Category] SARS, 임상, [키워드] acute respiratory syndrome adverse event adverse events age antiparasitic drug assigned caused coronavirus coronavirus disease COVID-19 double-blind duration of hospitalization Effectiveness Efficacy enrolment Frequency group hospitalized patient Ivermectin ivermectin treatment Mild Moderate COVID-19 n=36 negativity no difference outbreak overcome pandemic Patient PCR-positive PCR-positive patient Placebo placebo-controlled placebo-controlled trial polymerase chain Primary outcome proportion Randomized Randomized controlled trial Randomly receiving reported reverse transcription RT-PCR SARS-CoV-2 Secondary endpoints secondary outcome shown Side effects significant difference single-center standard care Standard of care survival symptomatic Symptoms therapeutic Treatment Trial worsening [DOI] 10.1186/s13063-022-06649-3 PMC 바로가기 [Article Type] Randomized Controlled Trial
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trialClinical Trial Published on 2022-08-012022-10-05 Journal: The Lancet. Haematology [Category] Coronavirus, Fulltext, MERS, 임상, [키워드] 1:1 105 patient 105 patients adverse event adverse events all-cause mortality analysed Asian assigned Belgium benefit black bleeding event Brazil Clinical practice Complete country COVID-19 COVID-19 vaccine death died dose Efficacy and safety eligibility eligible participant enrolled enrolment evaluate event rate FIVE Follow-up had no hazard ratio hospitalisation hospitalised in both group increased risk India Inflammation intention-to-treat population International IQR main analysis men middle multicentre no difference non-critically ill patient one patient Open-label Outpatient participant Patient patients with COVID-19 Pneumonia primary efficacy endpoint Prophylactic Prophylaxis random randomisation randomised Randomly receive Registered risk factor Safety Safety Monitoring Board Sanofi severe disease severity Sex similar studies South Africa Spain Standard of care Standard-of-care symptom onset symptomatic thromboembolic complications Trial uterine bleeding was done weighed were assessed white with COVID-19 women [DOI] 10.1016/S2352-3026(22)00173-9 PMC 바로가기 [Article Type] Clinical Trial
Outpatient convalescent plasma therapy for high-risk patients with early COVID-19. A randomized placebo-controlled trialResearch article Published on 2022-08-012022-10-05 Journal: Clinical microbiology and infection : the official [Category] SARS, 임상, [키워드] antibodies benefit clinical conducted convalescent plasma Convalescent plasma therapy Course COVID-19 death determine died disease severity double blind duration of symptoms Effectiveness Endpoint enrolment Follow-up hazard ratio high-risk patient highest Hospital admission Hospitalized ICU admission IMPROVE in viral median age multicentre objective Odds ratio Older Outpatient outpatients Patient PCR primary endpoint randomization randomized placebo-controlled trial randomized trial recruitment Result risk factor RNA secondary severe COVID-19 Symptom symptom duration symptom onset symptomatic Symptoms the disease therapy for COVID-19 vaccination Viral RNA [DOI] 10.1016/j.cmi.2022.08.005 [Article Type] Research article
Incremental monounsaturated to saturated fat ratio and fibre consumption is associated with a reduction in a composite score of modifiable cardiovascular risk factors: Prospective results from the Moli-sani study Research Published on 2022-07-292022-10-05 Journal: European journal of clinical nutrition [Category] 바이오마커, [키워드] 95%CI Analysis baseline blood lipids C-reactive protein cardiovascular disease cardiovascular risk change changes in clinical factors contributing to CVD dietary enrolled enrolment evaluate fat feature Health median men and women Modification Mortality Non-communicable disease outcome pleiotropic Prospective reduce reduction in reflected Result risk risk factor Risk factors saturated Sociodemographic sub-cohort Variation [DOI] 10.1038/s41430-022-01185-4 [Article Type] Research
Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/AustriaSchwaz/Austria 지역에서 BNT162b2를 사용한 SARS-CoV-2에 대한 신속한 대량 백신 접종 후 면역 반응의 6개월 추적Article Published on 2022-07-272022-09-11 Journal: Viruses [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] age Analysis antibody Antibody Response B-cell response B.1.351 Beta BNT162b2 carried correlated COVID-19 detect District enrolment evaluate immune response immune responses Infection mass mass vaccination natural infection new SARS-CoV-2 no correlation outbreak participant participated preserved provide Rapid reduction in response robust SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections second dose Seropositivity Serum level serum levels specific antibodies spring study participant subject Support T cell T cell response T cell responses T-cell Response the District the SARS-CoV-2 vaccination variant waned was measured [DOI] 10.3390/v14081642 PMC 바로가기 [Article Type] Article